Major review finds antihistamines unlikely to meaningfully help eczema patients

A sweeping review of clinical trials published in The BMJ this week challenges a practice so routine that millions of patients have come to expect it as standard care: taking oral antihistamines to manage eczema. Researchers who analyzed 47 randomized controlled trials involving more than 6,200 people found that adding these medications to existing eczema treatments produces, at best, a small reduction in symptoms that falls short of what patients would actually notice or benefit from in their daily lives.

Eczema, or atopic dermatitis, is a chronic inflammatory skin condition driven by an overactive immune system. It leaves skin dry, inflamed, and intensely itchy—the kind of itch that disrupts sleep, strains relationships, and erodes quality of life. The condition affects millions worldwide, and for decades, doctors have prescribed oral antihistamines as a standard addition to moisturizers and topical steroids, reasoning that blocking histamine might ease both the itching and the inflammation. The logic seemed sound enough that the practice became nearly universal. In the United Kingdom, roughly one in five eczema patients take antihistamines. In the United States, the figure climbs to nearly half.

Yet despite this widespread use, rigorous evidence supporting the practice has remained elusive. The new review, which examined trials comparing antihistamines to placebo in patients with moderate to severe eczema, found that H1 antihistamines—the most commonly prescribed class—likely produce only a small, clinically unimportant reduction in eczema severity and itch. More striking still, the medications may not reduce sleep disturbance or prevent flare-ups at all. For many patients, in other words, the drugs simply do not deliver the relief they were prescribed to provide.

The harms, by contrast, are tangible. First-generation antihistamines, which cross the blood-brain barrier more readily than newer formulations, probably increase cognitive impairment including sedation and drowsiness. Some patients stop taking the medication altogether because of these side effects, abandoning treatment not because it failed to work, but because it made them feel worse. The researchers note that these sedating effects can impair daytime functioning, a particular concern for working adults and school-age children.

The review represents an attempt to settle a question that has lingered in dermatology for years: whether antihistamines truly belong in routine eczema management. The researchers assembled evidence using standardized methods to assess trial quality and certainty, acknowledging limitations in the underlying studies but applying systematic approaches to address them. Their conclusion is direct: antihistamines likely do not meaningfully improve outcomes that matter to patients while probably increasing harm.

For the millions currently taking these medications—prescribed in good faith by doctors following established practice—the findings raise an uncomfortable question about whether they are receiving a treatment that actually helps. The review does not suggest that antihistamines have no role whatsoever in dermatology, but it does suggest that adding them to standard eczema care, as a routine measure, is not supported by evidence. That conclusion, if it gains traction in clinical guidelines, could reshape how dermatologists approach one of the most common chronic skin conditions, potentially sparing patients unnecessary side effects while redirecting focus to treatments with stronger evidence of benefit.